Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
Arch Osteoporos. 2021 Feb 26;16(1):44. doi: 10.1007/s11657-021-00911-y.
We investigate the rate of concordance between treatment recommendations of osteoporosis with 10-year probability of hip fracture calculated using FRAX scores with and without BMD. We found that predictions were concordant in 83.8% of patients. However, older age, lower BMD, and FRAX without BMD around the intervention threshold were associated with discordant results. In the discordant group, FRAX with BMD suggested treatment in more participants with lower age, higher BMI, and lower BMD when compared with FRAX without BMD.
The Fracture Risk Assessment Tool (FRAX) is used to calculate the 10-year probability of fracture using important clinical factors, with bone mineral density (BMD) as an optional input variable. We aimed to determine the rate of concordance between treatment recommendations of osteoporosis with 10-year probability of hip fracture calculated using FRAX scores with and without BMD and to identify relevant clinical risk factors associated with discordance.
This was a cross-sectional study conducted in patients between 40 and 90 years of age who were screened for osteoporosis by BMD measurement using dual energy X-ray absorptiometry (DXA) from 2010 to 2018 at a university hospital in Thailand. A FRAX questionnaire was administered to determine demographic data and osteoporotic risk factors. FRAX scores with and without BMD were calculated for each participant using the Thai reference, and patients were categorized into either the treatment or non-treatment group based on a cut-off of 3% 10-year probability of hip fracture. When FRAX scores with and without BMD results were consistent, they were considered concordant. Otherwise, they were deemed discordant. Clinical risk factors were compared between the concordant and discordant groups.
A total of 3545 participants were included in the study. The majority (83.8%) were in the concordant group. However, older age, lower BMD, and FRAX without BMD around the intervention threshold were significantly associated with discordant results. In the discordant group, FRAX with BMD suggested treatment in more participants with lower age, higher BMI, and lower BMD when compared with FRAX without BMD.
FRAX scores with and without BMD yielded concordant predictions regarding the 10-year probability of hip fracture suggesting pharmacological treatment. However, this concordance declined in elderly and osteoporotic participants and in those with FRAX without BMD around intervention threshold. BMD data may be required in these populations in order to facilitate accurate risk assessment.
我们旨在确定使用 FRAX 评分计算无 BMD 和有 BMD 的 10 年髋部骨折概率的骨质疏松治疗建议之间的一致性率,并确定与不一致相关的相关临床危险因素。
这是一项横断面研究,纳入了 2010 年至 2018 年期间在泰国一所大学医院接受双能 X 线吸收法(DXA)测量 BMD 筛查骨质疏松症的年龄在 40 至 90 岁之间的患者。对每位患者进行 FRAX 问卷以确定人口统计学数据和骨质疏松危险因素。使用泰国参考值为每位患者计算 FRAX 评分,无 BMD 和有 BMD,并根据 3%的 10 年髋部骨折概率的截定点将患者分为治疗组或非治疗组。当 FRAX 评分无 BMD 和有 BMD 的结果一致时,认为它们是一致的。否则,它们被认为是不一致的。比较了一致和不一致组之间的临床危险因素。
共纳入 3545 名参与者。大多数(83.8%)患者在一致组。然而,年龄较大、BMD 较低以及干预阈值周围无 FRAX-BMD 与不一致结果显著相关。在不一致组中,与无 BMD 的 FRAX 相比,有 BMD 的 FRAX 建议治疗更多年龄较小、BMI 较高且 BMD 较低的患者。
FRAX 评分无 BMD 和有 BMD 对药物治疗的 10 年髋部骨折概率预测结果一致。然而,在年龄较大和骨质疏松的患者以及 FRAX 无 BMD 接近干预阈值的患者中,这种一致性降低。在这些人群中,可能需要 BMD 数据以促进准确的风险评估。